TP53 and hepatocellular carcinoma: We optimize the p53 mRNA NP platform for HCC targeting, evaluate its therapeutic efficacy in p53-null HCCs growing in orthotopic and ectopic sites (alone or with aPD1 antibody), and study changes in the TME.